Ex-GSK Leader Launches ‘Molecular Clamp’ Vaccine Company Vicebio
Will Begin RSV Studies In 2023
Venture capital firm Medicxi has chosen Emmanuel Hanon to lead the company, hiring two more ex-GSK veterans to create what they hope is a ‘dream team’ in vaccines.
You may also be interested in...
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.
Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?
Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.